参芪化瘀方联合经导管动脉化疗栓塞治疗原发性肝癌患者的效果  

Effect of Shenqi Huayu Formula combined with transcatheter arterial chemoembolization in the treatment of patients with primary hepatocellular carcinoma

作　　者：卢冬彦[1] 叶小卫[1] LU Dongyan;YE Xiaowei(Department of Oncology,First Affiliated Hospital,Guangzhou University of Chinese Medicine,Guangdong Province,Guangzhou 510405,China)

机构地区：[1]广州中医药大学第一附属医院肿瘤中心,广东广州510405

出　　处：《中国医药导报》2023年第5期98-101,110,共5页China Medical Herald

基　　金：科技部战略规划司科技创新战略研究专项(ZLY202019);广东省中医药局科研项目(20202057)。

摘　　要：目的探讨参芪化瘀方联合经导管动脉化疗栓塞(TACE)治疗原发性肝癌(PHC)患者的效果。方法选取2020年6月至2021年12月广州中医药大学第一附属医院收治的PHC患者60例,采用随机数字表法将其分为对照组及治疗组,每组30例。两组均行TACE及术后对症治疗,治疗组在此基础上加服参芪化瘀方。参照实体瘤临床疗效评价标准1.1评价两组治疗4周后实体瘤疗效,比较两组治疗前及治疗4周后的中医证候积分、肝癌患者生命质量测定量表评分、血清甲胎蛋白(AFP)及白细胞介素(IL)-6、IL-1β、肿瘤坏死因子α(TNF-α)水平。结果治疗4周后,两组实体瘤临床疗效比较,差异无统计学意义(P>0.05)。治疗4周后,两组胁痛、腹胀、恶心呕吐、纳呆、神疲乏力积分及总积分低于治疗前,发热积分高于治疗前,且治疗组各项证候积分及总积分均低于对照组(P<0.05)。治疗4周后,两组躯体功能、心理功能、症状评分及总分均高于治疗前,且治疗组高于对照组(P<0.05)。治疗4周后,两组血清AFP、IL-6、IL-1β、TNF-α水平均低于治疗前,且治疗组低于对照组(P<0.05)。结论参芪化瘀方联合TACE能有效减轻PHC患者中医临床症状,提高其生活质量,同时下调血清AFP及炎症因子水平。Objective To evaluate the effect of Shenqi Huayu Formula combined with transcatheter arterial chemoembolization(TACE)in the treatment of patients with primary hepatocellular carcinoma(PHC).Methods Sixty patients with PHC admitted to the First Affiliated Hospital,Guangzhou University of Chinese Medicine from June 2020 to December 2021 were selected and divided into control group and treatment group by random number table method,with 30 cases in each group.Both groups received TACE and postoperative symptomatic treatment,and the treatment group was additionally given Shenqi Huayu Formula.The efficacy of solid tumor in the two groups after four weeks of treatment was evaluated according to the response evaluation criteria in solid tumor 1.1.Traditional Chinese medicine syndrome scores,quality of life-liver cancer scale scores,the levels of serum alpha-fetoprotein(AFP),interleukin(IL)-6,IL-1β,and tumor necrosis factor-α(TNF-α)were compared between the two groups before and four weeks after treatment.Results After four weeks of treatment,there was no significant difference in clinical efficacy between the two groups(P>0.05).After four weeks of treatment,the scores of hypochondriac pain,abdominal distension,nausea and vomiting,anorexia,spiritlessness and fatigue,and total scores in two groups were lower than those before treatment,and the score of fever was higher than that before treatment,and all syndrome scores and total scores in the treatment group were lower than those in the control group(P<0.05).After four weeks of treatment,physical function,mental function,symptoms scores,and total scores in both groups were higher than those before treatment,and the treatment group was higher than the control group(P<0.05).After four weeks of treatment,the levels of serum AFP,IL-6,IL-1β,and TNF-αin two groups were lower than those before treatment,and the treatment group was lower than the control group(P<0.05).Conclusion Shenqi Huayu Formula combined with TACE can effectively reduce the clinical symptoms of PHC patient

关 键 词：参芪化瘀方 经导管动脉化疗栓塞术 原发性肝癌 血清炎症因子 

分 类 号：R735.7[医药卫生—肿瘤]